| Autor: |
A, van Waarde, T J, Visser, P H, Elsinga, B, de Jong, T W, van der Mark, J, Kraan, K, Ensing, J, Pruim, A T, Willemsen, O E, Brodde, G M, Visser, A M, Paans, W, Vaalburg |
| Rok vydání: |
1997 |
| Předmět: |
|
| Zdroj: |
Journal of nuclear medicine : official publication, Society of Nuclear Medicine. 38(6) |
| ISSN: |
0161-5505 |
| Popis: |
We evaluated the suitability of fluorocarazolol for in vivo studies of cerebral beta-adrenoceptors because (S)-1'-[18F]fluorocarazolol has a higher affinity to beta-adrenoceptors than to serotonergic receptors (pKi beta 1 9.4, beta 2 10.0, 5HT1A 7.4, 5HT1B 8.1) and rapidly crosses the blood-brain barrier.The (S)-[18F]fluorocarazolol (74 MBq,37 TBq/mmol) was intravenously administered to healthy volunteers on two separate occasions with an interval of at least 1 wk. The initial injection was without pretreatment, but before the second injection, the volunteers received the beta blocker (+/-)-pindolol (3 x 5 mg orally, during 18 hr). The brain was studied with a PET camera in dynamic mode.Uptake of radioactivity delineated gray matter and was particularly high in the posterior cingulate, precuneus and striatum. Low uptake occurred in the thalamus, whereas the lowest uptake was observed in the white matter of the corpus callosum. After pindolol pretreatment, uptake was reduced and its distribution became homogeneous throughout the brain. The ratio of total-to-nonspecific binding was about 2 at 60 min, increasing to 2.5-2.75 at longer intervals.Fluorocarazolol is the first radioligand that can visualize cerebral beta-adrenoceptors and may enable monitoring of these binding sites during disease. |
| Databáze: |
OpenAIRE |
| Externí odkaz: |
|
